[HTML][HTML] CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's …
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism
rs12459419 C> T in the splice enhancer region regulates the expression of an alternatively
spliced CD33 isoform lacking exon2 (D2-CD33), thus eliminating the CD33 IgV domain,
which is the antibody-binding site for GO, as well as diagnostic immunophenotypic panels.
We aimed to determine the impact of the genotype of this splicing polymorphism in patients …
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism
rs12459419 C> T in the splice enhancer region regulates the expression of an alternatively
spliced CD33 isoform lacking exon2 (D2-CD33), thus eliminating the CD33 IgV domain,
which is the antibody-binding site for GO, as well as diagnostic immunophenotypic panels.
We aimed to determine the impact of the genotype of this splicing polymorphism in patients …
Abstract
Purpose
Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism rs12459419 C> T in the splice enhancer region regulates the expression of an alternatively spliced CD33 isoform lacking exon2 (D2-CD33), thus eliminating the CD33 IgV domain, which is the antibody-binding site for GO, as well as diagnostic immunophenotypic panels. We aimed to determine the impact of the genotype of this splicing polymorphism in patients with AML treated with GO-containing chemotherapy.
ncbi.nlm.nih.gov
